Highlights of the year in gastroenterology.
The past 12 months have been a period of steady progress in the field of gastroenterology. Helicobacter pylori continues to dominate many areas of clinical research and the indications for eradication are increasing. A potent, topically-acting corticosteroid for Crohn's disease, and new hope and potential treatments for IBS sufferers are other developments.
Ballinger
A
A
Digestive Diseases Research Centre, St Bartholemew's.
Farthing
M J
MJ
D000287:Administration, Topical; D000893:Anti-Inflammatory Agents; D019819:Budesonide; D003109:Colonic Diseases, Functional / Q000628:therapy; D004043:Dietary Fiber; D005770:Gastrointestinal Neoplasms / Q000517:prevention & control; D005938:Glucocorticoids; D016481:Helicobacter Infections / Q000188:drug therapy*; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy*; D010437:Peptic Ulcer / Q000382:microbiology; D011282:Pregnenediones / Q000008:administration & dosage; D012812:Sigmoidoscopy
D000893:Anti-Inflammatory Agents; D004043:Dietary Fiber; D005938:Glucocorticoids; D011282:Pregnenediones; D019819:Budesonide